
Leason Ellis Celebrates the Holidays 2023
December 22, 2023
Leason Ellis Appoints Yuval H. Marcus as Managing Partner
December 29, 2023IAM 300 Global Leaders 2024 Interviews Elizabeth Barnhard

As part of its Global Leaders 2024 series, IAM interviewed attorneys at the pinnacle of the patent law profession including Elizabeth Barnhard. Elizabeth chairs the Pharma/Biotech Practice Group of Leason Ellis. In the interview, Elizabeth spoke to a variety of different topics including mentoring young lawyers, opportunities for lawyers in generative AI, and the current state of the IP transactions space. In addressing the most crucial elements of a world-class IP portfolio in the biotech space, she thoughtfully advised that the biologic therapeutics portfolio should protect the biologic itself a well as functional derivatives, formulations, uses, delivery vehicles, manufacturing processes, diagnostic tests, future improvements, and new uses.